Has Barbara Huynh, DO received payments from drug or device companies?

Yes. Drug and device makers reported $3,719 in general payments to Barbara Huynh, DO across 36 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Barbara Huynh, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Barbara Huynh, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Barbara Huynh, DO

Geriatric Psychiatry · Los Angeles, CANPI 1407048002

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 60.1% of it on its own, with 7 other manufacturers making up the rest.

$3,719in general payments, 2019–2025

Across 36 payments — averaging $103.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$2K
Teva Pharmaceuticals USA, Inc.$382
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$325
Neurocrine Biosciences, Inc.$272
Alkermes, Inc.$238
Otsuka America Pharmaceutical, Inc.$125
plus $141 from 2 others

What the payments were for

Food & beverage$3,719100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	22	$2,236
Teva Pharmaceuticals USA, Inc.	4	$382
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	3	$325
Neurocrine Biosciences, Inc.	2	$272
Alkermes, Inc.	2	$238
Otsuka America Pharmaceutical, Inc.	1	$125
Idorsia Pharmaceuticals US Inc	1	$121
Indivior Inc.	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,719 in reported general payments places this provider in the 85th percentile of 46 geriatric psychiatry providers in California.

See all geriatric psychiatry providers in California →

Medicare billing

Part B allowed, 2024

$53,235

Medicare patients

Services billed

430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega SustennaPaliperidone Palmitate	104	$277,901
Aripiprazole	162	$18,432
VraylarCariprazine Hcl	11	$15,624
Risperidone ErRisperidone Microspheres	13	$14,418
Olanzapine	224	$10,474
Paliperidone ErPaliperidone	53	$8,789
Divalproex Sodium	91	$5,410
Quetiapine Fumarate	244	$5,054
Clozapine	45	$4,525
Lurasidone Hcl	18	$3,147
Asenapine Maleate	16	$3,132
Quetiapine Fumarate ErQuetiapine Fumarate	39	$2,904
Doxepin Hcl	13	$2,127
Propranolol Hcl	108	$1,613
Divalproex Sodium ErDivalproex Sodium	43	$1,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonInvega Sustenna	$2,236	$277,901104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 46 geriatric psychiatry providers in California.

Other geriatric psychiatry in Los Angeles

David SultzerLos Angeles$203K
Kyle BechazLos Angeles$1K
Kotra AjirLos Angeles$661
David TraderLos Angeles$573
Sarah KimLos Angeles$91
Miriam WinthropLos Angeles$27
Robert NeshkesLos Angeles$22
Christina HuiLos Angeles$0
Kristine YaffeSan Francisco$40K
James NelsonSan Francisco$31K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →